



JIALI YANG

Counsel · Shanghai

+86 21 2208 1072

jiali.yang@fangdalaw.com

PRACTICE AREA

JIALI SPECIALIZES IN CORPORATE AND COMMERCIAL MATTERS IN THE LIFE SCIENCES SECTOR. HER WORK PRIMARILY COVERS PRODUCT LICENSING, R&D AND COMMERCIALIZATION COLLABORATION, PRIVATE EQUITY, AND M&A. JIALI ALSO PROVIDES LEGAL ADVICE TO LIFE SCIENCES CLIENTS ON GENERAL CORPORATE MATTERS AND COMPLIANCE ISSUES IN DAILY OPERATIONS.

Education

- University of California, Berkeley, School of Law, LL.M.
- East China University of Political Science and Law, LL.B.

Professional Qualification

- Admitted to practice in the PRC
- Qualified in the State of New York (non-practicing)

Work Language

- Chinese
- English

Professional Background

- Jiali joined Fangda in 2019. Before rejoining in 2026, she worked at an international law firm in 2024 and 2025.

REPRESENTATIVE MATTERS AND CASES

Licensing and Collaboration

- Represented Huaota in entering into a global collaboration and license agreement with Almirall, S.A. for the research and development of an innovative monoclonal antibody in the field of dermatology.
- Represented TJ Bio in entering into a strategic collaboration with Sanofi for developing, manufacturing and commercializing the CD73 monoclonal antibody (Uliledlimab) in Greater China.
- Represented Insilico Medicine in its AI drug discovery collaboration and licensing transaction with SK Biopharmaceuticals.
- Represented AstraZeneca in granting to BioKangtai (300601.SZ) the exclusive license in China for AZD1222, an adenovirus vector-based COVID-19 vaccine.
- Represented Kyowa Kirin in its business restructuring in the APAC region through serial transactions comprising the sale of equities of Kyowa Kirin China to WinHealth and the grant of an exclusive license to WinHealth to commercialize and manufacture five products in China.
- Represented CStone in granting exclusive promotion rights for Gavreto[®] (Pralsetinib Capsules) within mainland China to Allist Pharma.
- Represented CStone in granting to 3SBio the exclusive rights to develop, manufacture, and commercialize Nofazinlimab (anti-PD-1 antibody) in mainland China.
- Represented CStone in its sale of TIBSOVO[®] (ivosidenib tablets) assets in the PRC and Singapore to Servier.
- Represented Overland Pharmaceuticals in granting an exclusive license to commercialize a rare disease drug in Singapore, Hong Kong, Macau and Taiwan to a leading Taiwan-based biopharma company.
- Represented AstraZeneca in obtaining the exclusive commercialization right in China to a hyperkalemia drug therapy from a leading Japanese pharmaceutical company.
- Represented AstraZeneca in multiple combination study projects with Abbisko Therapeutics, Ascentage Pharma, Wuxi BioCity, Genhouse, etc..

Private Equity Investment, M&A and General Corporate Matters

- Represented AstraZeneca in its full acquisition of several small- and medium-sized medical device distribution companies and pharmaceutical distribution companies.
 - Represented Hillhouse Capital as the lead investor in its multiple investments in biopharma companies and medical device companies, including in the Series B financing of Huahui Healthcare engaged in the research, development, production and sale of Anti-HBV drugs and Anti-HDV drugs; the Series B++ financing of Exegenesis Bio engaged in the research and development of several gene therapies; and the Series A financing of JJET, a top medical device company in the PRC electrophysiological industry.
 - Represented Quan Capital as the lead investor in its investment in the Series B financing of Alebund Biotech, which primarily focuses on discovering and developing novel therapies for kidney diseases and their complications, and the Series B financing of Oricell Therapeutics, a developer of novel drugs for tumor immunotherapy.
 - Represented Cainiao Network in its strategic acquisition of 30% shares in Baotong Inc., a warehousing and fulfillment solution subsidiary of Baozun Inc. (NASDAQ: BZUN and HKEX: 9991).
 - Represented YF Capital as the lead investor in its investment in the Series C financing of Heze Pharmaceuticals, a leading domestic CRO company.
 - Reviewed and revised day-to-day commercial agreements for pharmaceutical companies and medical device companies, such as AnHeart Therapeutics, Visen Pharmaceuticals and Basecure, with agreements including clinical trial contracts, CRO service contracts, CRC service contracts, distribution agreements, technical service agreements, procurement agreements and non-disclosure agreements, and advised on regulatory and compliance issues arising from daily business.
-